| Literature DB >> 32076053 |
Agata Karolina Pietrzak1,2, Andrzej Marszalek3, Joanna Kazmierska4, Jolanta Kunikowska5, Pawel Golusinski6, Wiktoria Maria Suchorska4,7, Marcin Michalak8, Witold Cholewinski9,4.
Abstract
This study aimed to evaluate the usefulness of the biphasic 2-deoxy-2-[18 F]fluoro-D-glucose positron emission tomography/computed tomography ([18 F]FDG PET/CT) examinations in terms of distinguishing benign and malignant lesions within the pharynx. 139 patients underwent sequential biphasic [18 F]FDG PET/CT examinations at 60 and 90 minutes (min) post intravenous injection (p.i.) of the [18 F]FDG. We evaluated the metabolic activity of 93 malignant lesions and 59 benign findings within pharynx as well as 70 normal blood vessels. We evaluated the maximal and mean standardized uptake value (SUVmax, SUVmean) and the retention index (RI-SUVmax). We used the receiver operating characteristics (ROC) analysis to obtain the prognostic metabolic indices cut-off which may differentiate between benign and malignant lesions. The SUVmax value cut-off at 60 and 90 min p.i. differentiating between normal and abnormal metabolic activity in the pharynx was 1.9 and 2.0, respectively. When compared benign and malignant lesions, the SUVmax on initial and delayed scans were 3.1 and 3.6, respectively. In this material, the increase of the SUVmax value over time of 1.7% suggested abnormality, while RI-SUVmax of 5.7% indicated malignant etiology. The biphasic [18 F]FDG PET/CT study protocol is useful in better stratification of normal and abnormal glucose metabolism activity in the pharynx.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32076053 PMCID: PMC7031226 DOI: 10.1038/s41598-020-59832-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Epidemiological data.
| Epidemiological data | |||||
|---|---|---|---|---|---|
| Characteristic | SCC Oropharynx | SCC Nasopharynx | SCC Hypopharynx | Inflammatory lesions | Postoperative lesions |
| Number of patients/lesions | 22/27 | 41/47 | 17/19 | 47/47 | 12/12 |
| Number of men/women | 15/7 | 27/14 | 14/3 | 27/20 | 11/1 |
| Mean age ± S.D. [years] | 59 ± 11 | 55 ± 15 | 63 ± 11 | 57 ± 13 | 62 ± 7 |
| Range [years] | 32–72 | 22–93 | 28–77 | 21–81 | 51–78 |
Sequential biphasic [18 F]FDG PET/CT study protocol.
| Phase and area of scanning | Characteristic | Value [min] |
|---|---|---|
| Initial 60 min p.i. | mean start time p.i. ± S.D.* | 63 ± 3 |
| Range p.i. | 58–67 | |
| Whole body scanning: mid-thigh - skull vertex | mean scanning lenght | 19 ± 2 |
| Range | 16–21 | |
| Delayed 90 min p.i. | mean start time p.i. ± S.D. | 91 ± 3 |
| Range p.i. | 78–95 | |
| Head and neck region: skull vertex - aortic arch | mean scanning lenght | 7 ± 3 |
| Range | 5–9 | |
| Initial and delayed | mean total delay between phases | 5 ± 2 |
| Range | 4–7 |
*S.D. – standard deviation.
Figure 1The malignant lesion within the pharynx showing increasing [18 F]FDG uptake over time. (a) - PET initial scans; (b) - PET delayed scans; (c) - CT initial scans; (d) - CT delayed scans; black arrows show the malignant mass infiltrating oropharynx.
Figure 2The phantom study.
Phantom study – SUV max value measurements.
| Sample volume [cm3] | Initial and delayed SUVmax values | ||
|---|---|---|---|
| Image (phase; spatial resolution) | a (60 min; 5 mm) | b (90 min; 5 mm) | c (90 min; 3 mm) |
| 2 | 7.7 | 7.7 | 7.7 |
| 4 | 2.6 | 2.6 | 2.7 |
| 10 | 14.0 | 13.9 | 14.0 |
| 15 | 3.5 | 3.5 | 3.5 |
| 20 | 15.6 | 14.4 | 15.5 |
Legend: a-initial scanning, b-delayed scanning, c-delayed scanning and increased spatial resolution (as shown on the Fig. 2).
Glucose metabolism changes over time within analyzed lesions.
| Diagnosis/Measurements | SUVmax initial and delayed | SUVmean initial and delayed | Tendency over time |
|---|---|---|---|
| SCC Oropharynx | p < 0.001 | p < 0.001 | increasing |
| SCC Nasopharynx | p < 0.001 | p < 0.001 | increasing |
| SCC Hypopharynx | p < 0.001 | p < 0.001 | increasing |
| Inflammation | p = 0.4 | p = 0.3 | no changea |
| Postoperative lesions | p = 0.1 | p = 0.1 | no changea |
| Blood vessels | p < 0.001 | p < 0.001 | decreasing |
aStatistically insignificant increase of the [18 F]FDG uptake over time.
The SUVmax, SUVmean at 60 and 90 min p.i. of the [18 F]FDG within analyzed groups.
| Lesion/Characteristic | SCC Oropharynx | SCC Nasopharynx | SCC Hypopharynx | Inflammatory | Postoperative |
|---|---|---|---|---|---|
| Value | |||||
| Median | 4.7 | 4.4 | 4.7 | 3.2 | 2.7 |
| Mode/multiplety | 8.8/2 | 2.6/3 | —* | 2.7/3 | 1.8/2 |
| Range | 2.7–8.9 | 2.2–14.4 | 2.2–14.0 | 2.0–7.0 | 1.8–3.5 |
| Median | 6.1 | 4.8 | 5.4 | 3.5 | 2.7 |
| Mode/multiplety | 3.3/2;4.2/2 | 11.1/2;5.0/2 | — | 2.6/2;2.8/2 | — |
| Range | 2.9–10.5 | 2.3–16.1 | 2.9–14.2 | 1.8–6.7 | 1.9–3.6 |
| Median | 3.1 | 2.7 | 3.2 | 2.6 | 2.1 |
| Mode/multiplety | 4.7/2 | 2.0/2 | — | 2.4/3 | 1.7/2 |
| Range | 1.6–6.9 | 1.3–12.9 | 1.7–10.4 | 1.5–5.8 | 1.4–2.6 |
| Median | 3.4 | 3.1 | 3.6 | 2.7 | 2.1 |
| Mode/multiplety | 2.5/2;3.3/2 | 5.3/2 | — | — | 1.9/2 |
| Range | 1.6–7.5 | 1.5–14.4 | 1.9–10.6 | 1.4–5.0 | 1.5–2.9 |
*No mode observed.
The SUVmax, SUVmean at 60 and 90 min p.i. of the [18 F]FDG within malignant, benign lesions and blood vessels.
| Lesion/Characteristic | Malignant lesions | Benign lesions | Blood vessels |
|---|---|---|---|
| Values | |||
| Median | 4.6 | 3.1 | 1.5 |
| Mode/multiplety | 2.6/3 | 2.7/4 | 1.5/5 |
| Range | 2.2–14.4 | 2.2–14.4 | 0.8–2.0 |
| Median | 5.1 | 3.3 | 1.3 |
| Mode/multiplety | 3.1/2;4.0/2 | 2.6/3 | 1.1/4 |
| Range | 2.3–16.1 | 2.3–16.1 | 0.5–1.9 |
| Median | 3.0 | 2.4 | 1.2 |
| Mode/ multiplety | 4.7/3 | 1.9/2;3.3/2;4.2/2 | 0.9/5;1.0/2;1.1/3 |
| Range | 1.3–12.9 | 1.3–12.9 | 0.7–1.7 |
| Median | 3.3 | 2.6 | 1.1 |
| Mode/ multiplety | 1.9/2;3.3/2 | 1.5/3;1.6/2;1.7/2 | 0.7/4;1.0/3,1.1/3 |
| Range | 1.5–14.4 | 1.5–14.4 | 0.3–1.9 |
The RI-SUVmax calculation.
| The RI-SUVmax evaluation | ||
|---|---|---|
| Lesions/value | mean RI-SUVmax ± S.D. | Range |
| SCC Oropharynx | 11% ± 10% | −10% to 36% |
| SCC Nasopharynx | 12% ± 14% | −9% to 51% |
| SCC Hypopharynx | 17% ± 19% | −14% to 66% |
| Inflammation | 1% ± 10% | −18% to 28% |
| Postoperative lesions | 6% ± 10% | −13% to 24% |
| Blood vessels | −13% ± 12% | −53% to 2% |
| Benign lesions | 2% ± 10% | −18% to 28% |
| Malignant lesions | 12% ± 14% | −14% to 66% |
Figure 3Normal and abnormal metabolic activity cut-off value – initial scanning.
Figure 4Normal and abnormal metabolic activity cut-off value – delayed scanning.
Figure 5Benign and malignant lesions – initial scanning.
Figure 6Benign and malignant lesions – delayed scanning.
The ROC analysis results.
| ROC analysis report | |||||
|---|---|---|---|---|---|
| Characteristics | cut-off value | sensitivity/specificity[%] | Youden Index | AUC[%] | P-value* |
| SUVmax 60 min | 1.9 | 99/100 | 0.99 | 100 | <0.001 |
| SUVmax 90 min | 2.0 | 99/100 | 0.99 | 99 | <0.001 |
| RI-SUVmax [%] | 1.7 | 73/99 | 0.7 | 89 | <0.001 |
| SUVmax 60 min | 3.1 | 56/76 | 0.3 | 69 | <0.001 |
| SUVmax 90 min | 3.6 | 41/86 | 0.3 | 65 | <0.001 |
| RI-SUVmax [%] | 5.7 | 71/64 | 0.4 | 71 | <0.001 |
*Kruskal-Wallis test’s results: differences between three groups.